+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
24 Sep 2015

USFDA approved new anti emetic drug Varubi (rolapitant)

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

Company: Tesaro
Approval Status: Approved September 2015
Specific Treatments: chemotherapy-induced nausea and vomiting
Therapeutic Areas: Gastroenterology, Oncology

Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist.

Varubi is specifically indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Varubi is supplied as a tablet for oral administration. The recommended dose is 180 mg rolapitant administered approximately 1 to 2 hours prior to the start of chemotherapy. Administer in combination with dexamethasone and a 5-HT3 receptor antagonist. No dosage adjustment for dexamethasone is required.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests